Condition
Dysferlinopathy
Total Trials
6
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
75% success
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Completed3
Unknown1
Terminated1
Enrolling By Invitation1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT04824040Enrolling By InvitationPrimary
Clinical, Immunological, Morphological and Genetic Characteristics of Patients With Dysferlinopathy (LGMD R2) in the RF
NCT07035145CompletedPrimary
Observational Cohort Study of Dysferlinopathy in China
NCT01676077UnknownPrimary
Clinical Outcome Study for Dysferlinopathy
NCT02710500Phase 1CompletedPrimary
rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies
NCT01863004Phase 1TerminatedPrimary
Proteasomal Inhibition for Patients With Mis-sense Mutated Dysferlin
NCT00527228Phase 2Completed
Deflazacort in Dysferlinopathies
Showing all 6 trials